Truist Securities Reiterates BioXcel Therapeutics (BTAI) at Buy, $125 Price Target

April 6, 2022 12:10 PM

Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $125.00 price target on BioXcel Therapeutics (NASDAQ: BTAI).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found